



## Representative Legal Matters

Paul Johnson

- Represented Hitachi in relation to its proposed USD 11 billion acquisition of ABB power grid business.
- Represented a global leader in the digital product market in connection with an acquisition of an online course creation and sales platform.
- Represented Abbott Laboratories on its USD 5.8 billion acquisition of Alere, Inc.
- Represented a global pharmaceutical company on the antitrust aspects of a USD 4.0 billion acquisition of a biopharmaceutical company.
- Represented a global pharmaceutical company on the antitrust aspects of a USD 1.95 billion acquisition of a biopharmaceutical company.
- Represented a global pharmaceutical company on the antitrust aspects of a USD 400 million acquisition of a biopharmaceutical company
- Represented a global pharmaceutical company on the sale of a prescription drug indicated for the emergency treatment of epileptic children with prolonged acute convulsive seizures to a European leader in pharmaceutical products.
- Represented Lonza and Chr. Hansen on their microbiome joint venture before the European Commission.
- Represented Jin Jiang on global merger control filings with respect to its USD 2.0 billion acquisition of Radisson.
- Represented Lonza on its USD 5.5 billion acquisition of Capsugel before the European Commission.
- Represented Warner Bros. on the European Commission's investigation into cross-border access to pay-TV content (case AT.40023), and successfully negotiated a settlement agreement with the case team.
- Represented a payment scheme on a variety of regulatory issues including dealing with National Banks and EU regulations in the payment sector including the Anti-Money laundering directive, PSDII, the Interchange fee Regulation and the ECB's proposal on cyber resilience.
- Represented a major global financial institution with respect to a number of investigations concerning potentially collusive behaviour.
- Represented a major global insurance institution on Brexit, and developed options to ensure continued access to the EU single market.
- Represented a major insurance company on the London Market dry run that tested the resilience of the world's pre-eminent insurance market to a major loss event.

# Baker McKenzie.

- Represented a major European financial trade association to oppose the proposed USD 9.5 billion acquisition of NYSE Euronext by Deutsche Börse blocked by the European Commission.
- Represented a major scientific instrument company in relation to its proposed USD 1.5 billion merger, and successfully negotiated an upfront remedy with the European Commission to obtain extended phase I clearance.